Krystal Biotech (NASDAQ:KRYS) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report published on Monday, Benzinga reports. The brokerage currently has a $200.00 price objective on the stock.

A number of other research analysts also recently weighed in on KRYS. William Blair reiterated an outperform rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Stifel Nicolaus restated a buy rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Finally, Citigroup upped their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech currently has a consensus rating of Buy and an average target price of $171.00.

Krystal Biotech Stock Performance

KRYS stock opened at $157.25 on Monday. Krystal Biotech has a fifty-two week low of $82.09 and a fifty-two week high of $189.97. The business’s 50 day moving average price is $160.57 and its two-hundred day moving average price is $130.62. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of 1,965.87 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter last year, the company posted ($1.25) EPS. Sell-side analysts forecast that Krystal Biotech will post 1.89 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold 38,087 shares of company stock valued at $6,210,591 in the last ninety days. 14.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Krystal Biotech by 111.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock worth $83,000 after purchasing an additional 379 shares during the period. Quest Partners LLC bought a new position in Krystal Biotech in the 4th quarter worth $127,000. Pier 88 Investment Partners LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $145,000. Fox Run Management L.L.C. purchased a new stake in Krystal Biotech in the 3rd quarter worth $219,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $303,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).